Hemab closes $157m in funding for bleeding disorder treatments
Following the completion of a Phase II trial of sutacimig, Hemab is preparing to progress to a registration trial in 2026.
Drug Development
MSD receives FDA approval for Winrevair’s updated indication
Chugai acquires Renalys, enhancing its kidney disease portfolio
EUROAPI’s Med4Cure project to strengthen pharma sovereignty
Ipsen to buy French biotech company ImCheck Therapeutics
Ventus and Genentech partner for small-molecule medicine discovery
Adcytherix gains $122m to propel ADC development
Tubulis closes $361m in Series C to advance cancer treatment
